Anatomical and functional characterization of central amygdala glucagon-like peptide 1 receptor expressing neurons
10.3389/fnbeh.2021.724030 · doi-reference
Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs
10.1007/s11033-025-10648-3 · doi-reference
Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes
10.1038/s41598-019-42770-1 · doi-reference
Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies
10.1093/eurjpc/zwad050 · doi-reference
Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
10.1038/s41467-020-14309-w · doi-reference
Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum
10.1152/ajpgi.00098.2013 · doi-reference
Distinct identity of GLP-1R, GLP-2R, and GIPR expressing cells and signaling circuits within the gastrointestinal tract
10.3389/fcell.2021.703966 · doi-reference
A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus
10.1016/j.appet.2022.106022 · doi-reference
Glucose-dependent insulinotropic peptide receptor expression in the hippocampus and neocortex of mesial temporal lobe epilepsy patients and rats undergoing pilocarpine induced status epilepticus
10.1016/j.peptides.2010.12.010 · doi-reference
GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells
10.1093/ejendo/lvac004 · doi-reference
Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance
10.1210/jc.2013-3350 · doi-reference
142-OR: Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HDM1005)—A Phase I, randomized, double-blind, placebo-controlled, single and multiple dose-escalation study
10.2337/db25-142-or · doi-reference
CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults
10.2337/db23-75-lb · doi-reference
Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial
10.1111/dom.70006 · doi-reference
1861-LB: Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obese adults—A Phase 2 trial
10.2337/db24-1861-lb · doi-reference
Once-monthly Maridebart cafraglutide for the treatment of obesity — A Phase 2 trial
10.1056/nejmoa2504214 · doi-reference
Tirzepatide as compared with semaglutide for the treatment of obesity
10.1056/nejmoa2416394 · doi-reference
Association of antihypertensive drug target genes with psychiatric disorders: A Mendelian randomization study
10.1001/jamapsychiatry.2021.0005 · doi-reference
Antipsychotics and glucose metabolism: How brain and body collide
10.1152/ajpendo.00164.2018 · doi-reference
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis
10.1016/s2215-0366(19)30416-x · doi-reference
Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution
10.1111/cts.13122 · doi-reference
Pharmacotherapy for co-occurring alcohol use disorder and post-traumatic stress disorder: Targeting the opioidergic, noradrenergic, serotonergic, and GABAergic/glutamatergic systems
10.35946/arcr.v39.2.09 · doi-reference
Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National epidemiologic survey on alcohol and related conditions
10.1001/archpsyc.61.8.807 · doi-reference
Changing landscape of alcohol-associated liver disease in younger individuals, women, and ethnic minorities
10.1111/liv.15933 · doi-reference
Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019–40: A modelling study
10.1016/s2468-2667(20)30062-1 · doi-reference
An age-period-cohort approach to studying long-term trends in obesity and overweight in England (1992–2019)
10.1002/oby.23657 · doi-reference
Prevalence patterns of overweight and obesity in the world: An age-period-cohort analysis
10.1371/journal.pone.0324733 · doi-reference
Chronic alcohol consumption potentiates the development of diabetes through pancreatic β-cell dysfunction
10.4331/wjbc.v6.i1.1 · doi-reference
Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: A randomized controlled trial
10.1001/jama.287.19.2559 · doi-reference
Metabolism disrupting chemicals and metabolic disorders
10.1016/j.reprotox.2016.10.001 · doi-reference
A complex interplay between nutrition and alcohol use disorder: Implications for breaking the vicious cycle
10.2174/0113816128292367240510111746 · doi-reference
Recent advances in alcohol metabolism: From the gut to the brain
10.1152/physrev.00053.2024 · doi-reference
GIP-derived GIP receptor antagonists—A review of their role in GIP receptor pharmacology
10.1016/j.peptides.2024.171212 · doi-reference
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
10.1038/s41467-020-18751-8 · doi-reference
Psychiatric comorbidities in alcohol use disorder
10.1016/s2215-0366(19)30222-6 · doi-reference
Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis
10.1053/j.gastro.2025.02.044 · doi-reference
Old and new biomarkers of alcohol abuse: Narrative review
10.3390/jcm12062124 · doi-reference
Scoping review of assessment tools for, magnitudes of and factors associated with problem drinking in population-based studies
10.1136/bmjopen-2023-080657 · doi-reference
Quantifying alcohol consumption: Self-report, transdermal assessment, and prediction of dependence symptoms
10.1016/j.addbeh.2015.06.042 · doi-reference
Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: A propensity score-matched analysis
10.3390/jcm14030944 · doi-reference
